Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-38434 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Phospho-CaMKI (Thr177) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references IQGAP1 binds AMPK and is required for maximum AMPK activation.
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
SIV-Mediated Synaptic Dysfunction Is Associated with an Increase in Synapsin Site 1 Phosphorylation and Impaired PP2A Activity.
Hedman AC, Li Z, Gorisse L, Parvathaneni S, Morgan CJ, Sacks DB
The Journal of biological chemistry 2021 Jan-Jun;296:100075
The Journal of biological chemistry 2021 Jan-Jun;296:100075
CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
Racioppi L, Nelson ER, Huang W, Mukherjee D, Lawrence SA, Lento W, Masci AM, Jiao Y, Park S, York B, Liu Y, Baek AE, Drewry DH, Zuercher WJ, Bertani FR, Businaro L, Geradts J, Hall A, Means AR, Chao N, Chang CY, McDonnell DP
Nature communications 2019 Jun 4;10(1):2450
Nature communications 2019 Jun 4;10(1):2450
SIV-Mediated Synaptic Dysfunction Is Associated with an Increase in Synapsin Site 1 Phosphorylation and Impaired PP2A Activity.
Shekarabi M, Robinson JA, Smith MD, Burdo TH
The Journal of neuroscience : the official journal of the Society for Neuroscience 2019 Aug 28;39(35):7006-7018
The Journal of neuroscience : the official journal of the Society for Neuroscience 2019 Aug 28;39(35):7006-7018
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-CaMK1 alpha pThr177 in extracts from K562 cells and Jurkat cells both treated with insulin (0.01U/mL, 15 min) using a Phospho-CaMK1 alpha pThr177 polyclonal antibody (Product # PA5-38434).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 Knockdown of IQGAP1 alters AMPK activation in human cell lines. A , HepG2 cells were transfected with control or IQGAP1 (IQ1)-targeted siRNA. 72 h after transfection, DMSO (-) or 10 muM A23187 (+) was added for 15 min. Cells were harvested and equal amounts of protein lysate were analyzed by Western blotting. Two separate blots (i and ii) were performed to probe for multiple proteins. Blot (i) was probed with anti-IQGAP1, anti-pAMPK, and antitubulin (loading control) antibodies. Blot (ii) was probed with anti-AMPK and antitubulin antibodies. B , the pAMPK and tubulin bands from the same blots were quantified with Image Studio 2.0 and corrected for the amount of tubulin in the corresponding sample. Data are expressed as mean +- SD ( n = 12) with vehicle-treated cells transfected with control siRNA set as 1. C , HeLa cells were transfected with control or IQGAP1-targeted siRNA. 72 h after transfection, cells were treated with DMSO (-) or 10 muM A23187 (+) for 15 min. Samples were processed as described for panel A. D , the pAMPK/tubulin ratios were calculated as described in panel B. Data are expressed as mean +- SD ( n = 11) with vehicle-treated cells transfected with control siRNA set as 1. E , HeLa cells were transfected with control or CaMKK2-targeted siRNA. 72 h after transfection, DMSO (-) or 10 muM A23187 (+) was added for 15 min. Samples were processed as described for panel A. F , pAMPK/tubulin ratios were calculated as described for panel B. Data are expresse